Literature DB >> 17079471

Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth.

Umer I Chaudhry1, T Peter Kingham, George Plitas, Steven C Katz, Jesse R Raab, Ronald P DeMatteo.   

Abstract

Natural killer dendritic cells (NKDC) are a novel subtype of dendritic cells with natural killer (NK) cell properties. IFN-gamma is a pleiotropic cytokine that plays an important role in the innate immune response to tumors. Based on our previous finding that the combination of Toll-like receptor 9 ligand CpG and interleukin (IL)-4 stimulates NKDC to produce IFN-gamma, we hypothesized that NKDC are the major IFN-gamma-producing dendritic cell subtype and may play a significant role in the host antitumor response. We found that under several conditions in vitro and in vivo NKDC accounted for the majority of IFN-gamma production by murine spleen CD11c(+) cells. IL-18 alone induced NKDC to secrete IFN-gamma, and the combination of IL-18 and CpG resulted in a synergistic increase in IFN-gamma production, both in vitro and in vivo. NK cells made 26-fold less IFN-gamma under the same conditions in vitro, whereas dendritic cells produced a negligible amount. The mechanism of IFN-gamma secretion by NKDC depended on IL-12. NKDC selectively proliferated in vitro and in vivo in response to the combination of IL-18 and CpG. Systemic treatment with IL-18 and CpG reduced the number of B16F10 melanoma lung metastases. The mechanism depended on NK1.1(+) cells, as their depletion abrogated the effect. IL-18 and CpG activated NKDC provided greater tumor protection than NK cells in IFN-gamma(-/-) mice. Thus, NKDC are the major dendritic cell subtype to produce IFN-gamma. The combined use of IL-18 and CpG is a viable strategy to potentiate the antitumor function of NKDC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079471     DOI: 10.1158/0008-5472.CAN-06-1908

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.

Authors:  Collin J LaCasse; Nona Janikashvili; Claire B Larmonier; Darya Alizadeh; Neale Hanke; Jessica Kartchner; Elaine Situ; Sara Centuori; Michael Har-Noy; Bernard Bonnotte; Emmanuel Katsanis; Nicolas Larmonier
Journal:  J Immunol       Date:  2011-11-09       Impact factor: 5.422

Review 2.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

3.  CD11c identifies a subset of murine liver natural killer cells that responds to adenoviral hepatitis.

Authors:  Bryan M Burt; George Plitas; Jennifer A Stableford; Hoang M Nguyen; Zubin M Bamboat; Venu G Pillarisetty; Ronald P DeMatteo
Journal:  J Leukoc Biol       Date:  2008-07-29       Impact factor: 4.962

Review 4.  Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.

Authors:  Jason R Baird; Arta M Monjazeb; Omid Shah; Heather McGee; William J Murphy; Marka R Crittenden; Michael J Gough
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-04-19       Impact factor: 7.038

Review 5.  Immune surveillance by the liver.

Authors:  Craig N Jenne; Paul Kubes
Journal:  Nat Immunol       Date:  2013-09-18       Impact factor: 25.606

6.  Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene.

Authors:  So Young Choi; You Suk Suh; Jae Ho Cho; Hyun Tak Jin; Jun Chang; Young Chul Sung
Journal:  Immune Netw       Date:  2009-10-30       Impact factor: 6.303

7.  TLR9 signaling promotes tumor progression of human lung cancer cell in vivo.

Authors:  Tao Ren; Lin Xu; Shuxian Jiao; Yanying Wang; Yingyun Cai; Yongjie Liang; Ya Zhou; Hong Zhou; Zhenke Wen
Journal:  Pathol Oncol Res       Date:  2009-03-25       Impact factor: 3.201

Review 8.  Dendritic cell tumor killing activity and its potential applications in cancer immunotherapy.

Authors:  Neale Hanke; Darya Alizadeh; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

9.  CpG oligodeoxynucleotides as immunotherapy in cancer.

Authors:  Bernd Jahrsdörfer; George J Weiner
Journal:  Update Cancer Ther       Date:  2008-03

10.  Characterization of Human CD8(+)TCR(-) Facilitating Cells In Vitro and In Vivo in a NOD/SCID/IL2rγ(null) Mouse Model.

Authors:  Y Huang; M J Elliott; E S Yolcu; T O Miller; J Ratajczak; L D Bozulic; Y Wen; H Xu; M Z Ratajczak; S T Ildstad
Journal:  Am J Transplant       Date:  2015-11-09       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.